Scholarlink

Purpose <p>We aim to validate the previously published FIRST-ROP algorithm in a tertiary-level center.</p> Methods <p>This is a retrospective consecutive study that includes premature infants screened for retinopathy of prematurity (ROP) at a tertiary referral center in Thessaloniki, Greece. Infants who did not meet criteria for microprematurity or nanoprematurity (i.e., infants born at ≥ 27 weeks gestational age and weighing ≥ 800&#xa0;g) were included in the study.</p> Results <p>Of the 1251 infants screened, 1094 (87.4%) met the inclusion criteria. ROP was detected in 103 patients (9.4%). Fourteen infants (1.3%) required treatment for active disease. The median postmenstrual age (PMA) at first ROP diagnosis was 34.7 weeks. No patients were diagnosed with type 1 ROP on either of the first two inpatient exams. The median PMA at first treatment was 38.1 weeks. The upper 95% confidence limit for missing a type 1 case when omitting the first and second ROP examinations was calculated to be 0.27% (95% CI, 0-0.27%). No patients were treated on the first or second exam.</p> Conclusion <p>In this medium-risk cohort of neonates not meeting criteria for microprematurity or nanoprematurity, in Greece, there were no patients treated on the first or second inpatient examinations. The FIRST ROP algorithm was validated to start screening at 34 weeks PMA. This is the first ex-US validation and may support the principle of risk-stratified ROP screening.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Validation of the FIRST-ROP algorithm in a tertiary care center in Greece

  • 期刊论文

  • 发表日期：

    2026年4月27日

查看全文
  • Celine Chaaya,
  • Stella Moutzouri,
  • Francisco Altamirano,
  • Srujay Pandiri,
  • Sandra Hoyek,
  • Elie Raad,
  • Arthur Brant,
  • Demetrios G. Vavvas,
  • Asimina Mataftsi,
  • Nimesh A. Patel

摘要

Purpose

We aim to validate the previously published FIRST-ROP algorithm in a tertiary-level center.

Methods

This is a retrospective consecutive study that includes premature infants screened for retinopathy of prematurity (ROP) at a tertiary referral center in Thessaloniki, Greece. Infants who did not meet criteria for microprematurity or nanoprematurity (i.e., infants born at ≥ 27 weeks gestational age and weighing ≥ 800 g) were included in the study.

Results

Of the 1251 infants screened, 1094 (87.4%) met the inclusion criteria. ROP was detected in 103 patients (9.4%). Fourteen infants (1.3%) required treatment for active disease. The median postmenstrual age (PMA) at first ROP diagnosis was 34.7 weeks. No patients were diagnosed with type 1 ROP on either of the first two inpatient exams. The median PMA at first treatment was 38.1 weeks. The upper 95% confidence limit for missing a type 1 case when omitting the first and second ROP examinations was calculated to be 0.27% (95% CI, 0-0.27%). No patients were treated on the first or second exam.

Conclusion

In this medium-risk cohort of neonates not meeting criteria for microprematurity or nanoprematurity, in Greece, there were no patients treated on the first or second inpatient examinations. The FIRST ROP algorithm was validated to start screening at 34 weeks PMA. This is the first ex-US validation and may support the principle of risk-stratified ROP screening.